soul trial oral semaglutide cardiovascular outcomes 2024 results mace reduction 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Cardiovascular Outcomes Associated with Semaglutide

70,71,72 Some studies have found that patients with neurodegenerative diseases, like Parkinsons disease, Alzheimers disease, and amyotrophic lateral sclerosis (ALS), tend to have lower serum uric acid levels, suggesting a potential neuroprotective effect of uric acid

10.1016/j.npep.2009.09.005 272 SuchankovaP.SteenslandP.FredrikssonI.EngelJ

Market Segmentation By Drug Type Dulaglutide Exenatide Liraglutide Lixisenatide Semaglutide Tirzepatide By Therapy Approach Monotherapy Combination Therapy By Route of Administration Subcutaneous Oral By Indication Type 2 Diabetes Obesity By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies By Region North America Europe Asia Pacific Latin America Middle East & Africa Buy this Premium Research Report:

Abrahmsen 2023)

[00:23:00] Again, I'm not saying it absolutely will, and I'm not making any promises here